Cyclobenzaprine and Selegiline: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
MAO inhibition can produce a potentially life-threatening drug interaction. Cyclobenzaprine with an MAO inhibitor can cause severe reactions including hyperpyretic crisis, seizures and death.
Clinical significance and safety
Cyclobenzaprine and Selegiline: MAO inhibition can produce a potentially life-threatening drug interaction. Cyclobenzaprine with an MAO inhibitor can cause severe reactions including hyperpyretic crisis, seizures and death. Cyclobenzaprine is contraindicated during MAOI treatment and within 14 days after an MAOI is discontinued. Urgent assessment is needed for a new combination of agitation or confusion, fever, marked sweating, tremor or abnormal muscle movements. The warning does not provide a pair-specific incidence or establish that toxicity is inevitable. MAOI contraindications and product-specific waiting intervals must be checked before co-treatment or switching; a patient should not plan a washout or abruptly stop regular treatment without the treating team.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.